ArticleBiofouling2014
Identification of small molecules inhibiting diguanylate cyclases to control bacterial biofilm development.
Article in Biofouling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 111 citations in OpenAlex.
- A novelVirulence · 2025Article
- Updates on therapeutic targeting of diguanylate cyclase for addressing bacterial infections: A comprehensive review.World journal of microbiology & biotechnology · 2025Review
- Echinacoside reduces intracellular c-di-GMP levels and potentiates tobramycin activity against Pseudomonas aeruginosa biofilm aggregates.NPJ biofilms and microbiomes · 2025Article
- Harnessing Cyclic di-GMP Signaling: A Strategic Approach to Combat Bacterial Biofilm-Associated Chronic Infections.Current microbiology · 2025Review
- Vicia ervilia lectin (VEA) has an antibiofilm effect on both Gram-positive and Gram-negative pathogenic bacteria.Archives of microbiology · 2024Article
- Quorum Sensing Inhibitors: An Alternative Strategy to Win the Battle against Multidrug-Resistant (MDR) Bacteria.Molecules (Basel, Switzerland) · 2024Review
- Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: a review.Frontiers in pharmacology · 2024Review
- Biofilm tolerance, resistance and infections increasing threat of public health.Microbial cell (Graz, Austria) · 2023Review
- An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents.Life (Basel, Switzerland) · 2022Review
- The Association between Biofilm Formation and Antimicrobial Resistance with Possible Ingenious Bio-Remedial Approaches.Antibiotics (Basel, Switzerland) · 2022Review
- Bacterial driver-passenger model in biofilms: a new mechanism in the development of colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Recent advances on the regulation of bacterial biofilm formation by herbal medicines.Frontiers in microbiology · 2022Review
- Factors mediatingCurrent research in microbial sciences · 2022Review
- Convergence of Biofilm Formation and Antibiotic Resistance inFrontiers in medicine · 2022Review
- Three faces of biofilms: a microbial lifestyle, a nascent multicellular organism, and an incubator for diversity.NPJ biofilms and microbiomes · 2021Review
- Strategies and Approaches for Discovery of Small Molecule Disruptors of Biofilm Physiology.Molecules (Basel, Switzerland) · 2021Review
- Identification of small molecules that interfere with c-di-GMP signaling and induce dispersal of Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2021Article
- Review
- Ways to control harmful biofilms: prevention, inhibition, and eradication.Critical reviews in microbiology · 2021Review
- Biofilms by bacterial human pathogens: Clinical relevance - development, composition and regulation - therapeutical strategies.Microbial cell (Graz, Austria) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Biofilm formation by pathogenic bacteria is an important virulence factor in the development of numerous chronic infections, thereby causing a severe health burden. Many of these infections cannot be resolved, as bacteria in biofilms are resistant to the host's immune defenses and antibiotic therapy. An urgent need for new strategies to treat biofilm-based infections is critically needed. Cyclic di-GMP (c-di-GMP) is a widely conserved second-messenger signal essential for biofilm formation. The absence of this signalling system in higher eukaryotes makes it an attractive target for the development of new anti-biofilm agents. In this study, the results of an in silico pharmacophore-based screen to identify small-molecule inhibitors of diguanylate cyclase (DGC) enzymes that synthesize c-di-GMP are described. Four small molecules, LP 3134, LP 3145, LP 4010 and LP 1062 that antagonize these enzymes and inhibit biofilm formation by Pseudomonas aeruginosa and Acinetobacter baumannii in a continuous-flow system are reported. All four molecules dispersed P. aeruginosa biofilms and inhibited biofilm development on urinary catheters. One molecule dispersed A. baumannii biofilms. Two molecules displayed no toxic effects on eukaryotic cells. These molecules represent the first compounds identified from an in silico screen that are able to inhibit DGC activity to prevent biofilm formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.